首页 | 本学科首页   官方微博 | 高级检索  
检索        

尼妥珠单抗及西妥昔单抗增强照射对人食管癌细胞系的作用
引用本文:陈静,马林,曲宝林,李建雄,蓝玉玲,杨咏强,孟玲玲,冯林春.尼妥珠单抗及西妥昔单抗增强照射对人食管癌细胞系的作用[J].中华放射医学与防护杂志,2014,34(7):489-492.
作者姓名:陈静  马林  曲宝林  李建雄  蓝玉玲  杨咏强  孟玲玲  冯林春
作者单位:100853 北京, 中国人民解放军总医院 解放军医学院放射治疗科;100853 北京, 中国人民解放军总医院 解放军医学院放射治疗科;100853 北京, 中国人民解放军总医院 解放军医学院放射治疗科;100853 北京, 中国人民解放军总医院 解放军医学院放射治疗科;100853 北京, 中国人民解放军总医院 解放军医学院放射治疗科;100853 北京, 中国人民解放军总医院 解放军医学院放射治疗科;100853 北京, 中国人民解放军总医院 解放军医学院放射治疗科;100853 北京, 中国人民解放军总医院 解放军医学院放射治疗科
摘    要:目的 观察尼妥珠单抗(h-R3)、西妥昔单抗(C225)联合照射对人食管鳞癌细胞系TE-13的作用。方法 分为无药对照组、h-R3组、C225组、单纯照射组、h-R3联合照射组、C225联合照射组,采用MTS法观察处理组对食管癌细胞增殖的影响,并计算细胞增殖率;采用克隆形成实验检测h-R3、C225对食管癌细胞系放射敏感性的影响,多靶单击模型拟合细胞存活曲线;通过流式细胞仪分析细胞周期分布及细胞凋亡变化。结果 与单纯照射组相比,单抗联合照射组的细胞增殖率明显降低(F=325.59,P<0.05),细胞凋亡率明显升高(F=120.59,P<0.05), SF2D0DqN值均显著降低,G0/G1、G2/M期细胞比例均增加,S期细胞比例减少。C225联合照射组的细胞凋亡率高于h-R3联合照射组(F=120.59,P<0.05),C225联合照射组SER(1.83)高于h-R3联合照射组SER(1.46)。结论 h-R3与C225均能提高照射对食管鳞癌细胞系TE-13的抗肿瘤作用,C225的杀伤作用略优于h-R3。

关 键 词:表皮生长因子受体  尼妥珠单抗  西妥昔单抗  食管癌  照射
收稿时间:8/6/2013 12:00:00 AM

Nimotuzumab and cetuximab enhanced radiation effects on human esophageal carcinoma cells
Chen Jing,Ma Lin,Qu Baolin,Li Jianxiong,Lan Yuling,Yang Yongqiang,Meng Lingling and Feng Linchun.Nimotuzumab and cetuximab enhanced radiation effects on human esophageal carcinoma cells[J].Chinese Journal of Radiological Medicine and Protection,2014,34(7):489-492.
Authors:Chen Jing  Ma Lin  Qu Baolin  Li Jianxiong  Lan Yuling  Yang Yongqiang  Meng Lingling and Feng Linchun
Institution:PLA General Hospital Cancer Center and Department of Radiotherapy, PLA Postgraduate School of Medicine, Beijing 100853, China;PLA General Hospital Cancer Center and Department of Radiotherapy, PLA Postgraduate School of Medicine, Beijing 100853, China;PLA General Hospital Cancer Center and Department of Radiotherapy, PLA Postgraduate School of Medicine, Beijing 100853, China;PLA General Hospital Cancer Center and Department of Radiotherapy, PLA Postgraduate School of Medicine, Beijing 100853, China;PLA General Hospital Cancer Center and Department of Radiotherapy, PLA Postgraduate School of Medicine, Beijing 100853, China;PLA General Hospital Cancer Center and Department of Radiotherapy, PLA Postgraduate School of Medicine, Beijing 100853, China;PLA General Hospital Cancer Center and Department of Radiotherapy, PLA Postgraduate School of Medicine, Beijing 100853, China;PLA General Hospital Cancer Center and Department of Radiotherapy, PLA Postgraduate School of Medicine, Beijing 100853, China
Abstract:Objective To observe the combination effects of radiation and nimotuzumab (h-R3) or cetuximab (C225) on human esophageal squamous carcinoma cell line TE-13.Methods TE-13 cells were divided into 6 groups, including no treatment control, h-R3, C225, irradiation, h-R3 combined with irradiation, and C225 combined with irradiation. For each group, cell proliferation was evaluated by MTS assay, cell radiosensitivity was determined by clonogenic assay and the survival curve was fitted with the multi-targets single-hit model, and cell cycle distribution and apoptosis were analyzed with flow cytometry assay. Results Compared with the irradiation group, after the combination treatment of mAbs and irradiation, the cell proliferation, the cell proliferations were obviously decreased (F=325.59,P<0.05), SF2, D0, Dq, and N values were obviously decreased, the cell apoptosis rates were significantly increased (F=120.59,P<0.05), and the percentages of cells in G0/G1 and G2/M phases were increased. The cell apoptosis rate of the C225 combined with irradiation group was higher than that of the h-R3 combined with irradiation group (F=120.59,P<0.05). The radiosensitization enhancement ratio (SER) of C225 was 1.83, higher than that of h-R3. Conclusions Both h-R3 and C225 can significantly enhance radiation damage of TE-13 cells and C225 is more effective than h-R3.
Keywords:Epidermal growth factor receptor  Nimotuzumab  Cetuximab  Esophageal carcinoma  Irradiation
点击此处可从《中华放射医学与防护杂志》浏览原始摘要信息
点击此处可从《中华放射医学与防护杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号